Shots:AbbVie & Neomorph have partnered in a collaboration & option-to-license deal to develop molecular glue degraders for oncology & immunology, using Neomorph's molecular glue discovery
As per the terms, Neomorph will receive upfront & is eligible for ~$1.64B in future option fee & milestones, plus net sales-based royalties
Molecular glue degraders are…
Shots:Tiziana identified new immune biomarkers in na-SPMS patients treated with nasal foralumab, using single-cell RNA sequencing of peripheral blood samples taken before treatment & at 3 as well as 6mos. post-administration
Study showed that after dosing in ongoing ISPPEA (expanded access program; n=10), gene expression changed starting 3mos. incl. modulation of FoxP3 Tregs,…
Shots:P-II neoadj. studies were UNICORN (n=56) & NEST (n=24) in resectable CRC. UNICORN: 93% & 29% pCR with 100% & 36% pMR in dMMR/MSI-H & pMMR/MSS tumors, respectively; NEST: At 18 (NEST-1) & 9mos. (NEST-2) follow-up, all were ctDNA-ve w/o recurrences; pMR improved to 47% in MSS tumors in NEST-2
P-I/II study of BOT/BAL…
The orthodontic landscape is undergoing a transformation, driven by cutting-edge technologies that promise to redefine patient care. Innovations such as 3D printing and AI-driven treatment plans are setting new benchmarks in orthodontic practice. These advancements not only enhance efficiency but also significantly improve treatment outcomes.In recent years, the field of orthodontics has witnessed remarkable advancements…
Shots:The US FDA has granted Orphan Drug Designation to Zai Lab’s ZL-1310 for treating small cell lung cancer (SCLC)
The designation is based on promising P-Ia/Ib trial data of ZL-1310 as monotherapy and with atezolizumab in treatment-experienced ES-SCLC patients, presented at the ENA Symposium 2024
ZL-1310 is a novel ADC targeting DLL3…
Holon Health Reports Development of Holon Vibe App for the People with Substance Use Disorders (SUD)
Shots:Holon Health reported the development of Holon Vibe, a multi-modal therapeutic app to provide health evaluations & care plan management for people with SUD in Indiana & Arizona, with more states to be added in 2025
Primary data for the app showed a 65%+ appointment show rate for users, a 61-day increase in…
Are you an athlete constantly in pain? This is common due to training intensity. Competitive duels can also take a toll on your body, causing injuries or the aforementioned. Therapies like dry needling and cupping can help you recover quickly without longer periods on the side track. This is because it will overwhelming options and…
Shots:The P-III (ALLEVIATE-1) study assessed analgesic efficacy of cebranopadol (400µg, QD) vs PBO for treating moderate-to-severe acute pain post abdominoplasty surgery
Study depicted significantly reduced pain intensity as evaluated by Pain Numeric Rating Scale (NRS) AUC4-48 (1.34 mean hourly difference) and a well-tolerated safety with nausea being the common AE
Tris will…
Shots:Coherus will present the P-II trial data of casdozokitug (10mg/kg; IV; Q3W) + Tecentriq (1200mg) + Avastin (15mg/kg) vs PBO for 1L LA/M HCC patients (n=30), in both viral & non-viral diseases, at ASCO GI 2025
Study (as of Sep 2024) met its 1EP of safety & all 2EPs depicting 38% ORR (5…
Shots: The EMA’s CHMP has granted positive opinions to 5 Biologics and 4 New Chemical Entities in December 2024, leading to treatments for patients and advances in the healthcare industry The major highlighted drugs were Galderma’s Nemluvio to treat Prurigo Nodularis and Atopic Dermatitis PharmaShots has compiled a list of 9 drugs that have been granted positive…
